MediVet Biologics Publishes the First Randomized Double-Blind Placebo Controlled Study Utilizing Acti-Stem for the Treatment of Canine Osteoarthritis in American Journal of Veterinary Research
Kansas State University published a study proving scientifically that ActiStem Therapy treatments make a significant improvement in pets’ osteoarthritis.
The double blind study was conducted on 22 dogs. Each dog had been diagnosed with osteoarthritis of the hip joints by a board certified orthopedic surgeon. Out of the 22 dogs, 10 received the ActiStem treatment the remaining 12 received a placebo. The study proved to show statistical significance in outcome measures such as canine brief pain inventory (CBPI) and a marked improvement in the treatment dogs utilizing blinded visual analogue scale (VAS). Additionally, a statically significant improvement was noted in the treatment group utilizing objective outcome measures for patients in the most severe pain quartile by examining peak vertical force (PVF) using a pressure sensitive walk way. No adverse effects or side effects were present in any of the dogs treated further identifying that ActiStem Therapy is safe in dogs.
Read the full story here